P372	Association between the PPARα L162V polymorphism, plasma lipid levels and atherosclerotic disease.
1I.Berthold, 1E.Giannakidou, 2H.Berthold, 3D.Müller-Wieland, 3J.Kotzka, 1W.Krone
1Klinik II und Poliklinik für Innere Meidzin, Uniersität Köln, Köln; 2Arzneimittelkommisison der deutschen Ärzteschaft, Köln; 3Deutsches Diabetes Forschungs Institut, Düsseldorf.

Peroxisome proliferator activated receptor alpha (PPARα) is a member of the nuclear receptor superfamily that regulates genes involved in lipid metabolism, homeostasis and inflammation. It thus represents a candidate gene for risk of dyslipidemia, atherosclerosis and coronary artery disease (CAD). Non-esterified fatty acids are PPARα ligands and their levels are increased in patients with type 2 diabetes mellitus (DM). The L162V polymorphism of the PPARα gene has been associated with various lipid abnormalities in both diabetic and non-diabetic individuals. Purpose of the present study was to examine whether the presence of the L162V polymorphism in the PPARα gene is associated with dyslipidemia and/or atherosclerotic disease in patients with type 2 DM as well as in non-diabetic controls